Drugs / BMS-986142
Trials 7
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 15 trials | ||||||
| Phase 1 | NCT02880670 | Aug → Sep 2016 | arthritic joint disease | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 1 | NCT02762123 | May → Aug 2016 | rheumatoid arthritis | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 1 | NCT02832180 | May → Oct 2016 | arthritic joint disease | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 1 | NCT02456844 | May → Jul 2015 | rheumatoid arthritis | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 1 | NCT02257151 | Sep 2014 → Aug 2015 | — | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 22 trials · 1 missed | ||||||
| Phase 2 | NCT02843659 | Oct 2016 → Jul 2017 | Sjogren syndrome | Bristol-Myers Squibb | Terminated | No outcome recorded |
| Phase 2 | NCT02638948 | Feb 2016 → May 2018 | rheumatoid arthritis | Bristol-Myers Squibb | Completed | Missed primary |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2016-06-08 | Bristol-Myers Squibb | Results Bristol-Myers Squibb Announces New Rheumatoid Arthritis Research and Real-World Data at the Annual European Congress of Rheumatology (EULAR 2016) bms.com ↗
the first data disclosure of Phase 1 data showing investigational BTK inhibitor, BMS-986142, for the treatment of rheumatoid arthritis and other inflammatory disease was well tolerated |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2016-06-08 | Bristol-Myers Squibb | Bristol-Myers Squibb Announces New Rheumatoid Arthritis Research and Real-World Data at the Annual European Congress of Rheumatology (EULAR 2016) bms.com ↗ |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 9 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BMS-986142 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02257151 ↗ |
| Action | Inhibit | “This study examined safety, efficacy, and pharmacokinetics of BMS-986142, an oral, reversible BTK inhibitor.” PMID 38251590 ↗ May 20231“Tyrosine-protein kinase BTK inhibitor” CHEMBL3900554 ↗ |
| Modality | Small molecule | — CHEMBL3900554 ↗ |
| Route | Oral | “BMS-986142 or placebo Single dose oral Solution or spray dried dispersion as specified” NCT02257151 ↗ |
| Target | BTK | “Tyrosine-protein kinase BTK inhibitor” CHEMBL3900554 ↗ |